"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of OCUFEN® ophthalmic solution. Other adverse reactions reported with the use of OCUFEN® ophthalmic solution include: fibrosis, hyphema, miosis, mydriasis, and ocular hyperemia.
Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported (see WARNINGS).
Read the Ocufen (flurbiprofen sodium ophthalmic solution) Side Effects Center for a complete guide to possible side effects
Interaction of OCUFEN® ophthalmic solution with other topical ophthalmic medications has not been fully investigated.
Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with OCUFEN® ophthalmic solution.
Read the Ocufen Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 8/3/2012
Additional Ocufen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.